Condividi contenuti The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Aggiornato: 1 ora 7 min fa

Abingworth Appoints Tim Haines and Kurt von Emster as Joint Managing Partners

Mar, 07/07/2015 - 13:45
LONDON, July 7, 2015 -- (Healthcare Sales & Marketing Network) -- Abingworth, the international investment group dedicated to life sciences and healthcare, today announced that Tim Haines and Kurt von Emster, have been appointed as joint Managing Partners...
Biopharmaceuticals, Devices, Venture Capital, Personnel
Abingworth

Darin Leigh Joins Metabolon as Chief Commercial Officer

Lun, 07/06/2015 - 16:32
New Role to Lead Commercial Strategy for Biomarker Discovery, Precision Medicine, and Diagnostics Products and Services RESEARCH TRIANGLE PARK, N.C., July 6, 2015 -- (Healthcare Sales & Marketing Network) -- Metabolon, Inc., the global leader in metabol...
Diagnostics, Personnel
Metabolon, metabolomics

Allergan to Acquire Oculeve Dry Eye Disease Development Programs

Lun, 07/06/2015 - 14:05
Enhances Allergan's World-Class Position in Eye Care Oculeve Lead Program OD-01 Device in Development for Increased Tear Production DUBLIN and SOUTH SAN FRANCISCO, Calif., July 6, 2015 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN),...
Biopharmaceuticals, Ophthalmology, Mergers & Acquisitions
Allergan, Oculeve, neurostimulation

OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development

Lun, 07/06/2015 - 13:55
SAN DIEGO, July 6, 2015 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Inc. ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Joann V. Lofgren to the newly cr...
Biopharmaceuticals, Oncology, Personnel
OncoSec Medical, ImmunoPulse

Strensiq(R) (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)

Lun, 07/06/2015 - 13:48
First Approved Treatment for Japanese Patients Suffering from HPP, a Life-Threatening Ultra-Rare Metabolic Disorder CHESHIRE, Conn.--(Healthcare Sales & Marketing Network)--Alexion Pharmaceuticals, Inc. (ALXN) announced today that Japan’s Ministry of He...
Biopharmaceuticals, Regulatory
Alexion Pharmaceuticals, Strensiq, asfotase alfa, hypophosphatasia

Tadataka Yamada, Ph.D., Former Head of GlaxoSmithKline and Takeda RandD, Re-Joins Frazier Healthcare

Lun, 07/06/2015 - 13:40
MENLO PARK, Calif. & SEATTLE--(Healthcare Sales & Marketing Network)--Frazier Healthcare, a leading provider of growth capital to healthcare companies, announces that Tadataka Yamada, Ph.D. has re-joined the firm. He will serve as a Venture Partner on the ...
Biopharmaceuticals, Venture Capital, Personnel
Frazier Healthcare

Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.

Ven, 07/03/2015 - 15:33
NEWARK, Calif., July 2, 2015 -- (Healthcare Sales & Marketing Network) -- Revance Therapeutics, Inc. (RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today tha...
Biopharmaceuticals, Drug Delivery, Dermatology, Personnel
Revance Therapeutics, botulinum toxin, TransMTS

Galderma Receives FDA Approval to Market Restylane(R) Lyft with Lidocaine to Correct Age Related Volume Loss in the Cheek Area

Gio, 07/02/2015 - 15:14
Restylane® Lyft is first and only FDA-approved filler to treat smile lines and add lift to the cheek area FORT WORTH, Texas, July 2, 2015 -- (Healthcare Sales & Marketing Network) -- Galderma, a global healthcare company focused on skin health, ann...
Biopharmaceuticals, Dermatology, FDA
Galderma, Restylane Lyft, Restylane, Perlane-L

Zalviso(TM) Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain

Gio, 07/02/2015 - 15:05
Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., July 2, 2015 -- (Healthcare Sales & Marketing Network) -- AcelRx Pharmaceuticals,...
Biopharmaceuticals, Drug Delivery
AcelRx Pharmaceuticals, Zalviso, sufentanil sublingual tablet

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

Gio, 07/02/2015 - 14:57
LOI Signed at ESMO GI Addresses Melanoma and Cancers of the Liver KNOXVILLE, Tenn.--(Healthcare Sales & Marketing Network)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceut...
Biopharmaceuticals, Oncology, Licensing
Provectus Biopharmaceuticals, Boehringer Ingelheim

GlySure Secures CE Mark and Launches World’s First Continuous Intravascular Glucose Monitoring System

Mer, 07/01/2015 - 15:23
System addresses unmet need for continuous glucose monitoring in the ICU, a potential market in excess of $5 billion ABINGDON, England--(Healthcare Sales & Marketing Network)--GlySure Limited today announced that it has secured the CE Mark for the world...
Devices, Monitoring, Regulatory
GlySure, CIGMS, Continuous Glucose Monitoring

MX Orthopedics Receives FDA Clearance on the dynaMX(TM) Compression Staple Featuring Malleable Nitinol Technology

Mer, 07/01/2015 - 15:16
CAMBRIDGE, Mass., July 1, 2015 -- (Healthcare Sales & Marketing Network) -- MX Orthopedics, Corp. (MXO), a leader in superelastic technologies for orthopedic implants, announces the recent FDA clearance (K143622) of its patent-pending dynaMX™ Compression ...
Devices, Orthopaedic, FDA
MX Orthopedics, dynaMX Compression Staple, Nitinol

Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product

Mer, 07/01/2015 - 14:52
Technology Pioneer Dr. Vijay Chandru to Continue as Strand's Chairman AURORA, Colo. and BANGALORE, India, July 1, 2015 -- (Healthcare Sales & Marketing Network) -- Strand Life Sciences, a global genomic profiling company that uses next generation seque...
Diagnostics, Oncology, Personnel
Strand Life Sciences, StrandAdvantage, Precision Medicine

Spine Wave Announces the Commercial Launch of the Leva(TM) Interbody Device System

Mer, 07/01/2015 - 14:39
The Leva(TM) Interbody Device System Allows Spine Surgeons to Maximize Bone Graft Volume in a Novel, Expandable Titanium Device SHELTON, CT--(Healthcare Sales & Marketing Network) - Spine Wave, Inc. is committed to the commercialization of high-quality...
Devices, Neurosurgery, Orthopaedic, Product Launch
Spine Wave, StaXx , Leva Interbody Device, spine surgery

Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer

Mer, 07/01/2015 - 14:10
HAMPTON, N.J., July 1, 2015 -- (Healthcare Sales & Marketing Network) -- Celldex Therapeutics, Inc. (CLDX) today announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wrigh...
Biopharmaceuticals, Oncology, Personnel
Celldex Therapeutics, RINTEGA

First Clinical Cases Performed Using Lombard Medical's Aorfix(TM) Plus Endovascular Stent Graft

Mar, 06/30/2015 - 13:47
Increased Diameter May Allow 10 Percent Increase in Aorfix-Treatable AAA Cases IRVINE, Calif., June 30, 2015 -- (Healthcare Sales & Marketing Network) -- Lombard Medical, Inc. (EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVA...
Devices, Interventional
Lombard Medical, Aorfix Plus, endovascular stent graft, AAA

Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis

Mar, 06/30/2015 - 13:34
Studies showed superiority on primary and major secondary endpoints in people with relapsing forms of multiple sclerosis Genentech will submit data to the U.S. Food and Drug Administration Phase III study in primary progressive multiple sclerosis ong...
Biopharmaceuticals, Neurology
Genentech, Roche Group, ocrelizumab, Rebif, multiple sclerosis

Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals

Lun, 06/29/2015 - 15:01
Delivery marks a major milestone in the installation of the first proton therapy system to treat cancer in adults and children in Ohio LITTLETON, Mass.--(Healthcare Sales & Marketing Network)--Mevion Medical Systems is announcing the delivery of the sup...
Devices, Oncology
Mevion Medical Systems, proton therapy, proton beam, radiotherapy

vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer

Lun, 06/29/2015 - 14:56
HIGH POINT, N.C.--(Healthcare Sales & Marketing Network)--vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today anno...
Biopharmaceuticals, Neurology, Endocrinology, Personnel
vTv Therapeutics, Alzheimer’s disease, diabetes

Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors

Lun, 06/29/2015 - 14:52
IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Aerie Pharmaceuticals, Inc. (AERI) (the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the t...
Biopharmaceuticals, Ophthalmology, Personnel
Aerie Pharmaceuticals, Rhopressa, glaucoma

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong